Anthera Pharmaceuticals, Inc. (ANTH)

[Paulieme]

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH): Zacks Growth Score
February 15, 2016 11:02 am------- Zacks Group follows a process of giving Growth Style Scores to listed companies in the industry. The entity has placed a positive score on Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH). This study takes into account the different parameters like firm’s financial numbers and the growth predictions. While conducting a financial study, the firm takes all the parameters including Balance Sheet and others. Once these parameters are analyzed, a score is given that can be anywhere between ‘A’ and ‘F’. A stock with an ‘A’ rating has a higher growth potential to achieve strong returns on the market.

Zacks frequently conducts a survey of market analysts to get price target and earnings forecast on any firm. Following the latest poll, the research group has given a mean growth prediction of N/A for Anthera Pharmaceuticals, Inc.. This is based on the anticipated growth numbers for next few years.

For the short-term, the research groups have a price target of $13.333. This figure records recommendations of 3 brokerages. The experts who think that the stock can give better returns over market has a positive target of $14 while the conservative target is $12.

There are many brokerage firms functioning in the market, and all of them have a different methodology for preparing a research report. Therefore, it becomes confusing for the investors to make an investment decision. In order to eliminate this confusion, Zacks uses a scale of 1-5, wherein investors keep their holdings if rating is ‘3’, opt for a buy if rating is 1 or 2 and can go for sell if rating is 4 or 5. Anthera Pharmaceuticals, Inc. has scored a rating of 1.

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) is likely to unveil its quarterly report on 2016-03-21. For the period ended on 2016–1-2-31, the firm posted quarterly EPS of $-0.29 and this time it is projected at $-0.28.-- http://theenterpriseleader.com/stock-watch/anthera-pharmaceuticals-inc-nasdaqanth-zacks-growth-score/69638/